title: Iron out for nontransfused thalassemia.
abstract: Individuals with β-thalassemia intermedia and hemoglobinopathies of equivalent severity who are infrequently or never transfused can still develop serious complications of iron overload. Taher et al report the first 1-year, randomized, double-blind, placebo-controlled trial of oral iron chelation therapy with deferasirox in this population.
authors.affiliation: Yale University School of Medicine.
authors.forename: Peter W
authors.initials: PW
authors.lastname: Marks
mesh_terms: D001565:Benzoates / Q000627:therapeutic use*; D000077588:Deferasirox; D005260:Female; D006801:Humans; D019190:Iron Overload / Q000188:drug therapy*; D008297:Male; D013789:Thalassemia / Q000188:drug therapy*; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D001565:Benzoates; D014230:Triazoles; D000077588:Deferasirox